SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

NCT00871546 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Mantle-Cell
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: SCH 727965
DRUG: Bortezomib
BIOLOGICAL: Alemtuzumab

Sponsor

Merck Sharp & Dohme LLC